DGI:Abdominelle Infektionen/Therapie/Erregerspezifische Therapie: Difference between revisions

From Infektiopedia
imported>Maximilian.schons@uk-koeln.de
(Die Seite wurde neu angelegt: „ Eine Anpassung der antiinfektiven Therapie entsprechend des nachgewiesenen Erregerspektrums sollte so früh wie möglich erfolgen. Tabelle 7 zeigt orientieren…“)
 
imported>Maximilian.schons@uk-koeln.de
No edit summary
Line 5: Line 5:


{| class="wikitable MsoTableGrid" style="width:100%;" border="1" cellspacing="0" cellpadding="0" width="652"
{| class="wikitable MsoTableGrid" style="width:100%;" border="1" cellspacing="0" cellpadding="0" width="652"
|+<span class="col-black">Tabelle 7: Spektren verfügbarer Antiinfektiva</span>
|+Tabelle 7: Spektren verfügbarer Antiinfektiva
| style="width:148.8pt;" width="198" |<span style="font-size:10.0pt">Präparat</span>
| style="width:148.8pt;" width="198" |<small>Präparat</small>
| colspan="16" style="width:340.0pt;" width="453" |<span style="font-size:10.0pt">Erreger</span>
| colspan="16" style="width:340.0pt;" width="453" |<small>Erreger</small>
| style="" width="1" |
| style="" width="1" |
|- style="height:275.8ptpx;"
|- style="height:275.8ptpx;"
| style="width:148.8pt;" width="198" valign="top" |
| style="width:148.8pt;" width="198" valign="top" |
| style="width:21.25pt;" width="28" |''<span style="font-size:10.0pt">P.  aerugionsa</span>'' <span style="font-size:10.0pt">WT</span>
| style="width:21.25pt;" width="28" |<small>P.  aerugionsa WT</small>
| style="width:21.25pt;" width="28" |''<span style="font-size:10.0pt">P.  aeruginosa</span>''<span style="font-size:10.0pt"><span style="mso-spacerun:yes"> </span> AmpC</span>
| style="width:21.25pt;" width="28" |<small>P.  aeruginosa  AmpC</small>
| style="width:21.25pt;" width="28" |''P. aeruginosa''<span style="mso-spacerun:yes"> </span> Porinverlust  (oprD-loss)
| style="width:21.25pt;" width="28" |<small>P. aeruginosa  Porinverlust  (oprD-loss)</small>
| style="width:21.25pt;" width="28" |''<span style="font-size:10.0pt">P.  aeruginosa</span>''<span style="font-size:10.0pt"><span style="mso-spacerun:yes"> </span> Effluxpumpen</span>
| style="width:21.25pt;" width="28" |<small>P.  aeruginosa  Effluxpumpen</small>
| style="width:21.25pt;" width="28" |''P. aeruginosa'' <span style="mso-spacerun:yes"> </span>Carbapenem-R  (Ø Carbapenemase)
| style="width:21.25pt;" width="28" |<small>P. aeruginosa  Carbapenem-R  (Ø Carbapenemase)</small>
| style="width:21.4pt;" width="29" |''P. aeruginosa''<span style="mso-spacerun:yes"> </span> MBL+
| style="width:21.4pt;" width="29" |<small>P. aeruginosa  MBL+</small>
| style="width:21.25pt;" width="28" |<span style="font-size:10.0pt">Enterobacteriaceae WT</span>
| style="width:21.25pt;" width="28" |<small>Entero-bacteriaceae WT</small>
| style="width:21.25pt;" width="28" |<span style="font-size:10.0pt">Enterobacteriaceae ESBL+</span>
| style="width:21.25pt;" width="28" |<small>Entero-bacteriaceae ESBL+</small>
| style="width:21.25pt;" width="28" |<span style="font-size:10.0pt">Enterobacteriaceae OXA-48-like+</span>
| style="width:21.25pt;" width="28" |<small>Entero-bacteriaceae OXA-48-like+</small>
| style="width:21.25pt;" width="28" |<span style="font-size:10.0pt">Enterobacteriaceae</span><span style="font-size:
| style="width:21.25pt;" width="28" |<small>Entero-bacteriaceae KPC</small>
  10.0pt;mso-ansi-language:EN-US"> </span><span style="font-size:10.0pt">KPC</span>
| style="width:21.25pt;" width="28" |<small>Entero-bacteriaceae Carbapenem-R (Ø Carbapenemase)</small>
| style="width:21.25pt;" width="28" |Enterobacteriaceae Carbapenem-R (Ø Carbapenemase)
| style="width:21.45pt;" width="29" |<small>Entero-bacteriaceae  MBL+  (VIM,IMP,NDM)</small>
| style="width:21.45pt;" width="29" |Enterobacteriaceae<span style="mso-spacerun:yes"> </span> MBL+  (VIM,IMP,NDM)
| style="width:21.25pt;" width="28" |<small>Acinetobacter  baumannii WT</small>
| style="width:21.25pt;" width="28" |<span style="mso-spacerun:yes"> </span>''Acinetobacter  baumannii'' WT
| style="width:21.25pt;" width="28" |<small>Acinetobacter  baumannii Carbapenem-R</small>
| style="width:21.25pt;" width="28" |<span style="mso-spacerun:yes"> </span>''Acinetobacter  baumannii'' Carbapenem-R
| style="width:21.25pt;" width="28" |<small>Steno-trophomonas maltophilia WT</small>
| style="width:21.25pt;" width="28" |''<span style="mso-spacerun:yes"> </span> Stenotrophomonas maltophilia'' WT
| colspan="2" style="width:21.4pt;" width="29" |<small>Steno-trophomonas maltophilia Carbapenem-R</small>
| colspan="2" style="width:21.4pt;" width="29" |''<span style="mso-spacerun:yes"> </span> Stenotrophomonas maltophilia'' Carbapenem-R
|- style="height:17.0ptpx;"
|- style="height:17.0ptpx;"
| style="width:148.8pt;" width="198" |Ceftazidim/ Avibactam
| style="width:148.8pt;" width="198" |<small>Ceftazidim/ Avibactam</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-white-bg" width="28" |
| style="width:21.25pt;" class="col-white-bg" width="28" |
Line 47: Line 46:
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" |
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" |
|- style="height:17.0ptpx;"
|- style="height:17.0ptpx;"
| style="width:148.8pt;" width="198" |<span style="font-size:10.0pt">Ceftolozan/  Tazobactam</span>
| style="width:148.8pt;" width="198" |<small>Ceftolozan/  Tazobactam</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
Line 65: Line 64:
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" |
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" |
|- style="height:17.0ptpx;"
|- style="height:17.0ptpx;"
| style="width:148.8pt;" width="198" |<span style="font-size:10.0pt">Imipenem/  Relebactam</span>
| style="width:148.8pt;" width="198" |<small>Imipenem/  Relebactam</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
Line 83: Line 82:
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" |
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" |
|- style="height:17.0ptpx;"
|- style="height:17.0ptpx;"
| style="width:148.8pt;" width="198" |<span style="font-size:10.0pt">Meropenem/ Varbobactam</span>
| style="width:148.8pt;" width="198" |<small>Meropenem/ Varbobactam</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
Line 101: Line 100:
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" |
| colspan="2" style="width:21.4pt;" class="col-red-bg" width="29" |
|- style="height:17.0ptpx;"
|- style="height:17.0ptpx;"
| style="width:148.8pt;" width="198" |<span style="font-size:10.0pt">Colisitin</span>
| style="width:148.8pt;" width="198" |<small>Colisitin</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
Line 119: Line 118:
| colspan="2" style="width:21.4pt;" class="col-white-bg" width="29" |
| colspan="2" style="width:21.4pt;" class="col-white-bg" width="29" |
|- style="height:17.0ptpx;"
|- style="height:17.0ptpx;"
| style="width:148.8pt;" width="198" |<span style="font-size:10.0pt">Cefiderocol</span>
| style="width:148.8pt;" width="198" |<small>Cefiderocol</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
Line 137: Line 136:
| colspan="2" style="width:21.4pt;" class="col-green-bg" width="29" |
| colspan="2" style="width:21.4pt;" class="col-green-bg" width="29" |
|- style="height:17.0ptpx;"
|- style="height:17.0ptpx;"
| style="width:148.8pt;" width="198" |<span style="font-size:10.0pt">Ceftobiprol</span>
| style="width:148.8pt;" width="198" |<small>Ceftobiprol</small>
| style="width:21.25pt;" class="col-red-bg" width="28" |
| style="width:21.25pt;" class="col-red-bg" width="28" |
| style="width:21.25pt;" class="col-red-bg" width="28" |
| style="width:21.25pt;" class="col-red-bg" width="28" |
Line 157: Line 156:
<br />
<br />
{| class="wikitable sortable mw-collapsible MsoTableGrid" style="width:100%;" border="1" cellspacing="0" cellpadding="0" width="369"
{| class="wikitable sortable mw-collapsible MsoTableGrid" style="width:100%;" border="1" cellspacing="0" cellpadding="0" width="369"
|+<span class="ve-pasteProtect" style="font-size:11.0pt;line-height:115%;font-family:&quot;Arial&quot;,sans-serif;
|+Tabelle 8: Erregerspezifische Antimykotikatherapie bei IAI
mso-fareast-font-family:Arial;mso-ansi-language:DE;mso-fareast-language:EN-US;
| style="width:148.8pt;" width="198" |<small>Präparat</small>
mso-bidi-language:AR-SA" data-ve-attributes="{&quot;style&quot;:&quot;font-size:11.0pt;line-height:115%;font-family:\&quot;Arial\&quot;,sans-serif;\nmso-fareast-font-family:Arial;mso-ansi-language:DE;mso-fareast-language:EN-US;\nmso-bidi-language:AR-SA&quot;}"> </span><span class="col-black">Tabelle 8: Erregerspezifische Antimykotikatherapie bei IAI</span>
| colspan="6" style="width:127.6pt;" width="170" |<small>Erreger</small>
| style="width:148.8pt;" width="198" |<span style="font-size:10.0pt;mso-ascii-font-family:Arial;mso-ascii-theme-font:
  major-latin;mso-hansi-font-family:Arial;mso-hansi-theme-font:major-latin;
  mso-bidi-font-family:Arial;mso-bidi-theme-font:major-latin">Präparat</span>
| colspan="6" style="width:127.6pt;" width="170" |Erreger
|- style="height:117.15ptpx;"
|- style="height:117.15ptpx;"
| style="width:148.8pt;" width="198" valign="top" |
| style="width:148.8pt;" width="198" valign="top" |
| style="width:21.25pt;" width="28" valign="top" |''<span style="font-size:10.0pt">Candida  albicans</span>''
| style="width:21.25pt;" width="28" valign="top" |<small>Candida  albicans</small>
| style="width:21.25pt;" width="28" valign="top" |''Candida glabrata''
| style="width:21.25pt;" width="28" valign="top" |<small>Candida glabrata</small>
| style="width:21.25pt;" width="28" valign="top" |''Candida parapsilosis''
| style="width:21.25pt;" width="28" valign="top" |<small>Candida parapsilosis</small>
| style="width:21.25pt;" width="28" valign="top" |''Candida krusei''
| style="width:21.25pt;" width="28" valign="top" |<small>Candida krusei</small>
| style="width:21.25pt;" width="28" valign="top" |''Aspergillus fumigatus''
| style="width:21.25pt;" width="28" valign="top" |<small>Aspergillus fumigatus</small>
| style="width:21.35pt;" width="28" valign="top" |''Aspergillus niger''
| style="width:21.35pt;" width="28" valign="top" |<small>Aspergillus niger</small>
|- style="height:31.2ptpx;"
|- style="height:31.2ptpx;"
| style="width:148.8pt;" width="198" valign="top" |<span style="font-size:10.0pt">Fluconazol</span>
| style="width:148.8pt;" width="198" valign="top" |<small>Fluconazol</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-white-bg" width="28" |
| style="width:21.25pt;" class="col-white-bg" width="28" |
Line 181: Line 176:
| style="width:21.35pt;" class="col-red-bg" width="28" |
| style="width:21.35pt;" class="col-red-bg" width="28" |
|- style="height:31.2ptpx;"
|- style="height:31.2ptpx;"
| style="width:148.8pt;" width="198" valign="top" |<span style="font-size:10.0pt">Voriconazol</span>
| style="width:148.8pt;" width="198" valign="top" |<small>Voriconazol</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-blue-light-bg" width="28" |
| style="width:21.25pt;" class="col-blue-light-bg" width="28" |
Line 189: Line 184:
| style="width:21.35pt;" class="col-green-bg" width="28" |
| style="width:21.35pt;" class="col-green-bg" width="28" |
|- style="height:31.2ptpx;"
|- style="height:31.2ptpx;"
| style="width:148.8pt;" width="198" valign="top" |<span style="font-size:10.0pt">Isavuconazol</span>
| style="width:148.8pt;" width="198" valign="top" |<small>Isavuconazol</small>
| style="width:21.25pt;" class="col-green-bg" width="28" valign="top" |
| style="width:21.25pt;" class="col-green-bg" width="28" valign="top" |
| style="width:21.25pt;" class="col-blue-light-bg" width="28" valign="top" |
| style="width:21.25pt;" class="col-blue-light-bg" width="28" valign="top" |
Line 197: Line 192:
| style="width:21.35pt;" class="col-green-bg" width="28" valign="top" |
| style="width:21.35pt;" class="col-green-bg" width="28" valign="top" |
|- style="height:31.2ptpx;"
|- style="height:31.2ptpx;"
| style="width:148.8pt;" width="198" valign="top" |<span style="font-size:10.0pt">Caspofungin</span>
| style="width:148.8pt;" width="198" valign="top" |<small>Caspofungin</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
Line 205: Line 200:
| style="width:21.35pt;" class="col-green-bg" width="28" |
| style="width:21.35pt;" class="col-green-bg" width="28" |
|- style="height:31.2ptpx;"
|- style="height:31.2ptpx;"
| style="width:148.8pt;" width="198" valign="top" |<span style="font-size:10.0pt">Anidulafungin</span>
| style="width:148.8pt;" width="198" valign="top" |<small>Anidulafungin</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
Line 213: Line 208:
| style="width:21.35pt;" class="col-green-bg" width="28" |
| style="width:21.35pt;" class="col-green-bg" width="28" |
|- style="height:17.0ptpx;"
|- style="height:17.0ptpx;"
| style="width:148.8pt;" width="198" |<span style="font-size:10.0pt">Micafungin</span>
| style="width:148.8pt;" width="198" |<small>Micafungin</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
Line 221: Line 216:
| style="width:21.35pt;" class="col-green-bg" width="28" |
| style="width:21.35pt;" class="col-green-bg" width="28" |
|- style="height:17.0ptpx;"
|- style="height:17.0ptpx;"
| style="width:148.8pt;" width="198" |<span style="font-size:10.0pt">Liposomales Amphotericin  B</span>
| style="width:148.8pt;" width="198" |<small>Liposomales Amphotericin  B</small>
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |
| style="width:21.25pt;" class="col-green-bg" width="28" |

Revision as of 05:12, 9 June 2021

Eine Anpassung der antiinfektiven Therapie entsprechend des nachgewiesenen Erregerspektrums sollte so früh wie möglich erfolgen. Tabelle 7 zeigt orientierend die aktuell neu verfügbaren Antiinfektiva für die Therapie von IAI durch MRE. Eine entsprechende Therapie sollte aber immer unter Berücksichtigung des aktuellen Antibiogrammes ausgewählt werden. Tabelle 8 gibt einen Überblick zur erregerspezifischen antimykotischen Therapie.

Auch im Setting der erregerspezifischen Therapie wird die Konsequenz eines Nachweises von Candida spp. und/oder Enterokokken aus dem Bauchraum oder aus Drainagesekreten kontrovers diskutiert. Der Nachweis beider Erregergruppen ist häufig das Ergebnis einer vorhergehenden intensiven Antibiotikaexposition und entsprechenden Selektion im Setting der tertiären Peritonitis. Bisherige Studien konnten zwar zeigen, dass ein entsprechender Nachweis mit einer ungünstigen Prognose assoziiert ist. Interventionelle Studien haben jedoch keine Verbesserung der Prognose basierend auf einer auf Enterokokken bzw. Candida spp. angepassten Therapie zeigen können. Daher bleibt unklar, ob der Nachweis dieser Erreger in diesem Setting tatsächlich eine klinische Relevanz hat, die über die eines Biomarkers für eine ungünstige Prognose hinausgeht. Aus diesem Grunde kann bei einem klinisch stabilen Patienten ohne aktuelle Hinweise einer floriden Infektion in Einzelfällen auch eine zuwartende Strategie verfolgt werden.

Tabelle 7: Spektren verfügbarer Antiinfektiva
Präparat Erreger
P. aerugionsa WT P. aeruginosa  AmpC P. aeruginosa  Porinverlust (oprD-loss) P. aeruginosa  Effluxpumpen P. aeruginosa  Carbapenem-R (Ø Carbapenemase) P. aeruginosa  MBL+ Entero-bacteriaceae WT Entero-bacteriaceae ESBL+ Entero-bacteriaceae OXA-48-like+ Entero-bacteriaceae KPC Entero-bacteriaceae Carbapenem-R (Ø Carbapenemase) Entero-bacteriaceae  MBL+ (VIM,IMP,NDM) Acinetobacter baumannii WT Acinetobacter baumannii Carbapenem-R Steno-trophomonas maltophilia WT Steno-trophomonas maltophilia Carbapenem-R
Ceftazidim/ Avibactam
Ceftolozan/ Tazobactam
Imipenem/ Relebactam
Meropenem/ Varbobactam
Colisitin
Cefiderocol
Ceftobiprol


Tabelle 8: Erregerspezifische Antimykotikatherapie bei IAI
Präparat Erreger
Candida albicans Candida glabrata Candida parapsilosis Candida krusei Aspergillus fumigatus Aspergillus niger
Fluconazol
Voriconazol
Isavuconazol
Caspofungin
Anidulafungin
Micafungin
Liposomales Amphotericin B
Retrieved from "https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Abdominelle_Infektionen/Therapie/Erregerspezifische_Therapie&oldid=4773"